Ro 13-6307

structure given in first source; RN given refers to (E,E,E)-isomer; RN for cpd without isomeric designation not available 10/92

Also Known As:

ethyltetrahydrotetramethyl-2-naphthalenyl-3-methyloctatrienoic acid

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Neuroblastoma 01/01/2001 - "In the present study, nude rats with human neuroblastoma SH-SY5Y xenografts were treated with 13-cis RA (4 mg po daily), 9-cis RA (5 mg po daily) or the novel analogue Ro 13-6307 (0.3 mg po daily) using either a continuous or short-term schedule. " 04/20/2003 - "Treatment of nude rats with neuroblastoma using Ro 13-6307, 0.12 mg p.o. " 04/20/2003 - "Neuroblastoma cells treated with 1 microM Ro 13-6307 exhibited neuronal differentiation, decreased proliferation and accumulation of cells in G1 phase in at least the same magnitude as 5 microM 13-cis RA. " 01/01/2001 - "Further in vivo studies are warranted, including pharmacokinetic and molecular analyses, before clinical trials with promising retinoids like 9-cis RA and Ro 13-6307 can be started in children with neuroblastoma." 04/20/2003 - "We investigated the effect of the synthetic retinoid Ro 13-6307 on neuroblastoma growth in vitro on SK-N-BE(2) and SH-SY5Y cells. "
2.	Weight Loss (Weight Reduction) 01/01/2001 - "However, severe toxicity with significant weight loss was seen in all rats treated with 9-cis RA and Ro 13-6307. "

1.	Therapeutics